Full Breakdown
Moderna-Merck Melanoma Vaccine Clears Phase 3, Sending Shares Soaring
8/20/2026, 5:52:02 AM
Phase 3 Trial Shows Positive Results for Melanoma Vaccine
On August 19 the joint Phase 3 study INTerpath-001 reported that the personalized mRNA cancer vaccine intismeran autogene, given with Merck’s checkpoint inhibitor Keytruda, met its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant-metastasis-free survival (DMFS) in patients with completely resected high-risk melanoma. 1,137 participants were randomized 2:1 to receive the vaccine plus Keytruda or Keytruda alone for roughly one year. The topline data indicated statistically significant improvements in both RFS and DMFS compared with Keytruda monotherapy.
Development Background
The collaboration began in 2016 with an upfront payment of $200 million and a $250 million option exercised in 2022. The vaccine, also known as V940 or mRNA-4157, sequences each patient’s tumor, selects up to 34 mutations, and encodes them into an mRNA construct delivered by lipid nanoparticles. Earlier Phase 2b data (KEYNOTE-942) showed a 49 % lower risk of recurrence or death and a 59 % lower risk of distant metastasis versus Keytruda alone, earning Breakthrough-Therapy and PRIME designations from the FDA and EMA.
Key Data Points
- Enrollment: 1,137 high-risk melanoma patients (stage IIB-IV) after surgical removal.
- Randomization: 2 : 1 (vaccine + Keytruda vs. Keytruda alone).
- Endpoints Met: Primary (RFS) and secondary (DMFS) at a pre-specified interim analysis.
- Risk Reductions (Phase 2 reference): 49 % reduction in recurrence/death; 59 % reduction in distant metastasis.
- Safety: No new safety signals; profiles consistent with earlier studies.
- Regulatory Outlook: Companies plan to present full data at an upcoming international medical meeting and begin formal discussions with regulators “in the coming months.”
Why It Matters
The results provide the first Phase 3 validation of an mRNA-based individualized cancer vaccine, extending Moderna’s platform beyond infectious-disease products. For Merck, the data offer a potential new indication to extend the commercial life of Keytruda ahead of its expected patent expiry in the late 2020s. Analysts project peak melanoma sales of roughly $3 billion by 2035, and the technology could be applied to trials in lung, bladder, kidney and other solid tumors.
Official Statements & Responses
- “It's a big moment for medicine, a big moment for patients,” — Moderna CEO Stephane Bancel
- “I have excitement for the field, excitement for our patients,” — Dr. Ryan Sullivan, director of cutaneous medical oncology at Mass General Brigham Cancer Institute
Gaps & Unreleased Details
The companies have released only topline efficacy and safety summaries; detailed recurrence-rate curves, absolute event numbers and overall-survival data remain pending. Consequently, investors and clinicians lack a full quantitative picture of the benefit, and regulators will require the complete dataset before granting approval.
Outlook
The next steps involve presenting the full dataset at a major oncology conference and filing regulatory submissions, with a possible approval timeline as early as 2027. Success could cement mRNA as a versatile therapeutic modality across oncology while providing Moderna a critical growth engine beyond its COVID-19 vaccine portfolio.
